News for Galmed Pharmaceuticals Ltd. (GLMD)

PR NewswireTEL AVIV, Israel, May 27, 2025 Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and at

Galmed Pharmaceuticals (GLMD) identifies a proprietary 70-protein biomarker signature for Aramchol. This discovery opens potential multi-billion-dollar

PR NewswireTEL AVIV, Israel, May 22, 2025 TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Compa

Galmed Pharmaceuticals (GLMD) reported a net loss reduction to $1.1 million in Q1 2025. The company's cash position increased to $20.1 million after rai

California-based Marin Software Incorporated (MRIN) is up over 141 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Galmed Pharmaceuticals (GLMD) has revealed promising outcomes from its initial oncology research efforts. These studies demonstrated that Aramchol significantly

Galmed Pharmaceuticals (GLMD) recently revealed promising findings from initial oncology research, demonstrating that Aramchol significantly amplifies the effec

PR NewswireTEL AVIV, Israel, May 6, 2025 Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while th...

Key Highlights: Galmed Pharmaceuticals teams up with Virginia Commonwealth University to tackle drug resistance in gastrointestinal cancers. The focus is

U.S. stocks traded higher this morning, with the Dow Jones index more than 150 points on Monday. Following the market opening Monday, the Dow traded up 0.47% t...

Galmed Pharmaceuticals (GLMD) has entered into a research partnership with Virginia Commonwealth University (VCU) to explore the potential of Aramchol in addres

PR NewswireTEL AVIV, Israel, April 10, 2025 ”“ AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formu

Galmed Pharmaceuticals (GLMD) reports positive preliminary results from Part 1 of the AM-001 study for Aramchol Meglumine. The new formulation shows nea

PR NewswireTEL AVIV, Israel, April 2, 2025 TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Com

PR NewswireTEL AVIV, Israel, March 20, 2025 TEL AVIV, Israel, March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "C

Galmed Phar stock hits 52-week low at $2.6 amid market challenges

Galmed Phar stock hits 52-week low at $2.73 amid challenges

Galmed reports positive results for Aramchol in NASH study